These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 32321191)
1. Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients. Jew S; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Spektor TM; Berenson JR Br J Haematol; 2021 Mar; 192(6):1064-1067. PubMed ID: 32321191 [TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma. Guo P; Wang Y; He H; Chen D; Liu J; Qiang W; Lu J; Liang Y; Du J Clin Exp Immunol; 2024 Aug; 217(3):221-232. PubMed ID: 38743453 [TBL] [Abstract][Full Text] [Related]
3. Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment. Jew S; Chang T; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Spektor TM; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Berenson JR Br J Haematol; 2021 Jan; 192(2):272-280. PubMed ID: 32441777 [TBL] [Abstract][Full Text] [Related]
5. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Ghermezi M; Li M; Vardanyan S; Harutyunyan NM; Gottlieb J; Berenson A; Spektor TM; Andreu-Vieyra C; Petraki S; Sanchez E; Udd K; Wang CS; Swift RA; Chen H; Berenson JR Haematologica; 2017 Apr; 102(4):785-795. PubMed ID: 28034989 [TBL] [Abstract][Full Text] [Related]
6. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy. Bujarski S; Udd K; Soof C; Chen H; Spektor TM; Safaie T; Li M; Stern J; Wang C; Xu N; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Regidor B; Sutanto C; Berenson JR Target Oncol; 2021 Jul; 16(4):503-515. PubMed ID: 34097243 [TBL] [Abstract][Full Text] [Related]
7. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma. Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536 [TBL] [Abstract][Full Text] [Related]
8. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma. Wiedemann Á; Szita VR; Horváth R; Szederjesi A; Sebő A; Tóth AD; Masszi T; Varga G Pathol Oncol Res; 2023; 29():1611171. PubMed ID: 37188125 [No Abstract] [Full Text] [Related]
9. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients. Salazar-Camarena DC; Palafox-Sánchez CA; Cruz A; Marín-Rosales M; Muñoz-Valle JF Sci Rep; 2020 Apr; 10(1):6236. PubMed ID: 32277232 [TBL] [Abstract][Full Text] [Related]
10. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Chen H; Li M; Xu N; Ng N; Sanchez E; Soof CM; Patil S; Udd K; Bujarski S; Cao J; Hekmati T; Ghermezi M; Zhou M; Wang EY; Tanenbaum EJ; Zahab B; Schlossberg R; Yashar MA; Wang CS; Tang GY; Spektor TM; Berenson JR Leuk Res; 2019 Jun; 81():62-66. PubMed ID: 31035033 [TBL] [Abstract][Full Text] [Related]
11. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Sanchez E; Tanenbaum EJ; Patil S; Li M; Soof CM; Vidisheva A; Waterman GN; Hekmati T; Tang G; Wang CS; Chen H; Berenson J Expert Rev Mol Diagn; 2018 Apr; 18(4):319-329. PubMed ID: 29504446 [TBL] [Abstract][Full Text] [Related]
12. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma. Alomari M; Kunacheewa C; Manasanch EE Leuk Lymphoma; 2023 Feb; 64(2):261-272. PubMed ID: 36282671 [TBL] [Abstract][Full Text] [Related]
13. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody. Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410 [TBL] [Abstract][Full Text] [Related]
14. Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. Soof CM; Spektor TM; Parikh SA; Slager SL; Rabe KG; Call TG; Kenderian SS; Ding W; Muchtar E; Ghermezi M; Kay NE; Berenson JR Exp Hematol; 2022 Jul; 111():32-40. PubMed ID: 35525334 [TBL] [Abstract][Full Text] [Related]
15. Analytical assessment and validation of the ProteinSimple ELLA serum B-cell maturation antigen assay. Kirchhoff DC; Zhang W; Chandras A; Mendu DR Pract Lab Med; 2024 Jan; 38():e00354. PubMed ID: 38283321 [TBL] [Abstract][Full Text] [Related]
16. Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia. Udd KA; Bujarski S; Wirtschafter E; Spektor TM; Ghermezi M; Rassenti LZ; David ME; Nosrati JD; Rahbari AA; Wang J; Vardanyan S; Harutyunyan NM; Linesch J; Li M; Sanchez E; Chen H; Kipps TJ; Berenson JR Target Oncol; 2019 Oct; 14(5):551-561. PubMed ID: 31473933 [TBL] [Abstract][Full Text] [Related]
17. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Ali SA; Shi V; Maric I; Wang M; Stroncek DF; Rose JJ; Brudno JN; Stetler-Stevenson M; Feldman SA; Hansen BG; Fellowes VS; Hakim FT; Gress RE; Kochenderfer JN Blood; 2016 Sep; 128(13):1688-700. PubMed ID: 27412889 [TBL] [Abstract][Full Text] [Related]
18. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Sanchez E; Li M; Kitto A; Li J; Wang CS; Kirk DT; Yellin O; Nichols CM; Dreyer MP; Ahles CP; Robinson A; Madden E; Waterman GN; Swift RA; Bonavida B; Boccia R; Vescio RA; Crowley J; Chen H; Berenson JR Br J Haematol; 2012 Sep; 158(6):727-38. PubMed ID: 22804669 [TBL] [Abstract][Full Text] [Related]
19. Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma. Salem DA; Maric I; Yuan CM; Liewehr DJ; Venzon DJ; Kochenderfer J; Stetler-Stevenson M Leuk Res; 2018 Aug; 71():106-111. PubMed ID: 30053652 [TBL] [Abstract][Full Text] [Related]
20. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma. Sanchez E; Gillespie A; Tang G; Ferros M; Harutyunyan NM; Vardanyan S; Gottlieb J; Li M; Wang CS; Chen H; Berenson JR Clin Cancer Res; 2016 Jul; 22(13):3383-97. PubMed ID: 26960399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]